Aims. One method of femoral head preservation following avascular necrosis
(AVN) is core decompression and insertion of a
Non-traumatic osteonecrosis of the femoral head
is a potentially devastating condition, the prevalence of which
is increasing. Many joint-preserving forms of treatment, both medical
and surgical, have been developed in an attempt to slow or reverse
its progression, as it usually affects young patients. However, it is important to evaluate the best evidence that is
available for the many forms of treatment considering the variation
in the demographics of the patients, the methodology and the outcomes
in the studies that have been published, so that it can be used
effectively. The purpose of this review, therefore, was to provide an up-to-date,
evidence-based guide to the management, both non-operative and operative,
of non-traumatic osteonecrosis of the femoral head. Cite this article:
The introduction of a trabecular tantalum rod
has been proposed for the management of early-stage osteonecrosis of
the femoral head but serves as a single-point of support of the
necrotic lesion. We describe a technique using two or three 4.2
mm (or later 4.7 mm) tantalum pegs for the prevention of collapse
of the necrotic lesion. We prospectively studied 21 patients (26
hips) with non-traumatic osteonecrosis of the femoral head treated
in this manner. Of these, 21 patients (24 hips) were available for
radiological and clinical evaluation at a mean follow-up of 46 months
(18 to 67). Radiological assessment showed that only eight hips
deteriorated according to the Association Research Circulation Osseous
classification, and four hips according to the Classification of
the Japanese Investigation Committee of Health and Welfare. Functional
improvement was obtained with an improvement in the mean Harris
hip score from 65.2 (33.67 to 95) to 88.1 (51.72 to 100), the mean
Merle D’Aubigné-Postel score from 13 (6 to 18) to 16 (11 to 18),
a mean visual analogue score for pain from 5.2 (0 to 9.5) to 2.6
(0 to 7), and the mean Short-Form 36 score from 80.4 (56.8 to 107.1)
to 92.4 (67.5 to 115.7). Of these 24 hips followed for a minimum
of 18 months, three were considered as failures at the final follow-up,
having required total hip replacement. One of the hips without full
follow-up was also considered to be a failure. In more than two-thirds
of the surviving hips a satisfactory clinical outcome was achieved
with promising radiological findings. The estimated mean implant
survival was 60 months (95% confidence interval 53.7 to 66.3).